氨甲环酸在战斗创伤中的军事应用:是否重要?
这项回顾性观察研究纳入3773例战斗伤员,评估氨甲环酸使用与死亡率及血栓栓塞事件的关系。总样本、大量输血亚组、倾向匹配亚组及美/北约军事亚组的死亡率风险比均无统计学显著差异。但氨甲环酸使用与总样本、大量输血亚组及美/北约军事亚组的肺栓塞风险增加相关,并与总样本及美/北约军事亚组的深静脉血栓风险增加相关。作者认为死亡率风险比估计与CRASH-2试验一致,但需持续监测氨甲环酸在军事创伤中的使用,特别是预防血栓栓塞事件。
要点
- 在3773例战斗伤员总样本中,氨甲环酸使用与死亡率无显著关联(HR 0.97;95%CI 0.62-1.53;P=0.86)。
- 在784例大量输血患者中,氨甲环酸与死亡率无显著关联(HR 0.84;95%CI 0.46-1.56;P=0.51)。
- 氨甲环酸使用与总样本肺栓塞风险增加相关(HR 2.82;95%CI 2.08-3.81;P<0.001),但与倾向匹配样本无显著关联(HR 3.36;95%CI 0.80-14.10;P=0.10)。
- 氨甲环酸使用与总样本深静脉血栓风险增加相关(HR 2.00;95%CI 1.21-3.30;P=0.02)。
- 作者认为死亡率HR估计与CRASH-2试验一致,但需持续监测氨甲环酸在军事创伤中的使用,特别是预防血栓栓塞事件。
适用人群与场景
- 战斗创伤伤员,数据来自创伤登记库,共3773例。
- 亚组包括大量输血患者(n=784)、倾向匹配样本(n=1030)和美/北约军事人员(n=1262)。
研究设计与关键结果
- 研究类型:回顾性观察研究,样本量3773例,数据来自创伤登记库。
- 总样本死亡率:HR 0.97(95%CI 0.62-1.53;P=0.86),氨甲环酸使用与死亡率无统计学显著关联。
- 大量输血亚组死亡率:HR 0.84(95%CI 0.46-1.56;P=0.51),无统计学显著关联。
- 倾向匹配样本死亡率:HR 0.68(95%CI 0.27-1.73;P=0.34),无统计学显著关联。
- 美/北约军事亚组死亡率:HR 0.76(95%CI 0.30-1.92;P=0.48),无统计学显著关联。
- 肺栓塞:总样本HR 2.82(95%CI 2.08-3.81;P<0.001),大量输血亚组HR 3.64(95%CI 1.96-6.78;P=0.003),美/北约军事亚组HR 2.55(95%CI 1.73-3.69;P=0.002),倾向匹配样本HR 3.36(95%CI 0.80-14.10;P=0.10)无统计学显著关联。
- 深静脉血栓:总样本HR 2.00(95%CI 1.21-3.30;P=0.02),美/北约军事亚组HR 2.18(95%CI 1.20-3.96;P=0.02)。
证据类型、等级与局限
- 证据类型:回顾性观察研究,证据等级为治疗性证据IV级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为死亡率HR估计与CRASH-2试验一致,但氨甲环酸使用与肺栓塞和深静脉血栓风险增加相关,需持续监测军事创伤中氨甲环酸的使用,特别是预防血栓栓塞事件。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Tranexamic acid (TXA) has been previously reported to have a mortality benefit in civilian and combat-related trauma, and was thus added to the Joint Theater Trauma System Damage Control Resuscitation Clinical Practice Guideline. As part of ongoing system-wide performance improvement, the use of TXA has been closely monitored. The goal was to evaluate the efficacy and safety of TXA use in military casualties and provide additional guidance for continued use.
METHODS: A total of 3,773 casualties were included in this retrospective, observational study of data gathered from a trauma registry. The total sample, along with three subsamples for massive transfusion patients (n = 784), propensity-matched sample (n = 1,030), and US/North Atlantic Treaty Organization (NATO) military (n = 1,262), was assessed for administration of TXA and time from injury to administration of TXA. Outcomes included mortality and occurrence of pulmonary embolism and deep vein thrombosis. Multivariable proportional hazards regression models with robust standard error estimates were used to estimate hazard ratios (HR) for assessment of outcomes while controlling for covariates.
RESULTS: Results of univariate and multivariate analyses of the total sample (HR, 0.97; 95% confidence interval [CI], 0.62-1.53; p = 0.86), massive transfusion sample (HR, 0.84; 95% CI, 0.46-1.56; p = 0.51), propensity-matched sample (HR, 0.68; 95% CI, 0.27-1.73; p = 0.34), and US/NATO military sample (HR, 0.76; 95% CI, 0.30-1.92; p = 0.48) indicate no statistically significant association between TXA use and mortality. Use of TXA was associated with increased risk of pulmonary embolism in the total sample (HR, 2.82; 95% CI, 2.08-3.81; p < 0.001), massive transfusion sample (HR, 3.64; 95% CI, 1.96-6.78; p = 0.003), US/NATO military sample (HR, 2.55; 95% CI, 1.73-3.69; p = 0.002), but not the propensity-matched sample (HR, 3.36; 95% CI, 0.80-14.10; p = 0.10). TXA was also associated with increased risk of deep vein thrombosis in the total sample (HR, 2.00; 95% CI, 1.21-3.30; p = 0.02) and US/NATO military sample (HR, 2.18; 95% CI, 1.20-3.96; p = 0.02).
CONCLUSION: In the largest study on TXA use in a combat trauma population, TXA was not significantly associated with mortality, due to lack of statistical power. However, our HR estimates for mortality among patients who received TXA are consistent with previous findings from the CRASH-2 trial. At the same time, continued scrutiny and surveillance of TXA use in military trauma, specifically for prevention of thromboembolic events, is warranted.
LEVEL OF EVIDENCE: Therapeutic, level IV.
参考来源
- Howard JT, Stockinger ZT, Cap AP, et al. Military use of tranexamic acid in combat trauma: Does it matter? J Trauma Acute Care Surg. 2017. PMID: 28930952. doi:10.1097/TA.0000000000001613
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。